Intuitive Surgical

Q3 2026
Speakers

Oct 20, 2026 · 61 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Hello ?and welcome to intuitive third quarter 2026 earnings release. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask the question during the session, you will need to press star 1 1 on your telephone. ?You will then hear an automatic message advising your hand is raised. ?To withdraw your question, please press star 1 1 again. ?

I
will now like to turn the the call over to Dan Connolly, head of Investor Relations. You may begin.

Passages & reports (9)
  • Hello
  • and
  • welcome to intuitive third quarter 2026 earnings release. At this time, all participants a…
  • You
  • will then hear an automatic message advising your hand is raised.
  • To
  • withdraw your question, please press star 1 1 again.
  • I
  • will now like to turn the the call over to Dan Connolly, head of Investor Relations. You m…

Speaker 1

Unverified voice label

Good afternoon, and welcome to Intuitive's Q3 2026 Earnings Conference Call. Joining me today are Dave Rosa, our CEO, Jamie Samath, our CFO, Dr. Jamie Wong, our Chief Medical Officer, ?and Gary Loeb, our Chief Legal and Compliance Officer. Before we begin, I would like to remind you that comments made on today's call may contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties.

These risks and uncertainties are described in our Securities and
Exchange Commission filings, including our most recent 10K filed on February 3rd, 2026, ?and 10Q filed on July 21st, 2026. Our SEC filings can be found through our website at intuitive.com or at the SEC's website. Investors are cautioned not to place undue reliance on such forward-looking statements. This conference call will be available for audio replay on our website in the events section under our investor relations page. ?

We
have posted today's press release and supplementary financial data tables to our website. Our format for this afternoon's conference call is as follows. Dave will review our business and operational highlights. Jamie will review our financial results and procedure highlights. Jamie Wong will review clinical highlights. I will review our updated financial outlook for 2026, and finally, we will host a question and answer session.

With that, I will turn it over to Dave.

Passages & reports (10)
  • Good afternoon, and welcome to Intuitive's Q3 2026 Earnings Conference Call. Joining me to…
  • and
  • Gary Loeb, our Chief Legal and Compliance Officer. Before we begin, I would like to remind…
  • Exchange Commission filings, including our most recent 10K filed on February 3rd, 2026,
  • and
  • 10Q filed on July 21st, 2026. Our SEC filings can be found through our website at intuitiv…
  • in the events section under our investor relations page.
  • We
  • have posted today's press release and supplementary financial data tables to our website. …
  • updated financial outlook for 2026, and finally, we will host a question and answer sessio…

Speaker 2

Unverified voice label

Good afternoon, and thank you for joining us today. Q3 was a strong quarter for Intuitive, with broad-based adoption across our multi-port, single port, and ion platforms. In Q3, total procedures increased 15%, driven by 14% growth in DaVinci procedures and 31% growth in ion procedures. ?In the U.S., DaVinci procedure growth was 10%, and outside the U.S., DaVinci procedure growth was 20%. We exited the quarter with more than 13,200 DaVinci and Ion systems installed worldwide.

Over time, our customers have adopted, operationalized, and standardized on the
DaVinci ecosystem to provide their patients with improved ?care. That adoption has been driven by our commitment to innovation, robust training, and clinical evidence, and it is apparent in how customers use DaVinci today. ?In the quarter almost 7,000 customers in more than 70 countries perform DaVinci procedures at a rate of over 10,000 procedures per ?day.

On
the clinical evidence front, more than 48,000 peer-reviewed publications have evaluated the effectiveness of DaVinci surgery, including the recent benign compare study, which Jamie Wong will discuss in more detail shortly. ?As I described last quarter, we continue to see increasing segmentation across our customer base. Needs vary by procedure, site of care, geography, and healthcare system. We have been investing to support the segmentation, ?and we have positioned Intuitive to serve current and future customers with both our existing technologies and those in development.

Meeting those needs also requires that we evolve our commercial approach to tailor how we engage, price, and provide solutions for customers in each segment.
?In Q3, global customer demand across our DaVinci portfolio remains strong. DaVinci system placements increased 28% worldwide, ?with DaVinci 5 and SP accounting for 65% of global placements. Installations of XIR and X more than doubled in the quarter. Customers continue to adopt DaVinci 5 and its growing capabilities, with demand for both capacity expansion and system upgrades.

We exited the quarter with more than 2,000
DaVinci 5 systems installed worldwide, used by over 18,000 surgeons since launch. ?We continue to see strong interest in XIR, both in the U.S. and internationally, where customers are leveraging its familiarity, capabilities, and cost profile to build programs around a focused set of procedures. ?Our DaVinci Single Port platform is playing an increasingly important role for our customers and their patients.

Our investments in additional clearances and instrumentation are yielding results. As SP procedures expand in the U.S. and internationally. Adoption of the new SP stapler continues to broaden,
?and in Q4, we plan to make a U.S. submission ?for the SP vessel sealer, which we believe is a key enabler for wider adoption of our SP platform. Increasingly, customers that adopt both multiport and single port describe benefits to their overall DaVinci programs, with SP opening new approaches for the surgeon while existing procedure demand fills their multi-port capacity. ?

In
Q3, we finalized a set of pricing actions for a subset of high-volume benign procedures where costs may be a constraint to broader access to DaVinci surgery. We believe these actions, in conjunction with increased availability of XIR, will expand our addressable opportunity ?and enable DaVinci technology to reach more patients around the world. Jamie will describe the anticipated impact shortly. Outside the U.S., we are elevating our focus and increasing our investments ?to help customers establish and expand their DaVinci programs. ?

As
of Q3, nearly 4,000 international customers ?have a DaVinci program, and nearly 25% operate two or more systems. These customers are moving beyond urology and cancer procedures into benign hysterectomy in Germany, choli cystectomy in the UK and India, ?and inguinal hernia repair in Japan. To support this growth, we are continuing to build the foundation of market access country by country through regulatory clearances, reimbursement, training, and clinical and economic validation.

DaVinci placements outside the U.S. increased 29% in the quarter
with broad-based global demand. In Europe, Germany led the region with 20 system installations. We also placed systems in more than 20 other European countries, and benign procedures led procedure growth. In Asia, Japan improved on both system placements and procedure growth for the second consecutive quarter, while India had another strong quarter with 42% procedure growth, surpassing 200,000 cumulative DaVinci procedures.

In China, the operating environment remains challenging. To support expected long-term growth in Asia, we recently announced plans for a significant new INA manufacturing
facility ?in Penang, Malaysia. We expect this facility to begin operations in 2028. Beyond DaVinci, we are investing in Ion outside the U.S. through multi-year country-by-country work that is foundational to broadening access and shortening the time between detection and treatment of lung cancer.

During Q3,
we received reimbursement for Ion in Korea, and we expect further reimbursement actions in other geographies in the coming quarters. This quarter, we received several CE marks, including force feedback instrumentation ?and cardiac procedures on DaVinci 5, as well as transvaginal gynecological procedures on SP. ?We now have DaVinci 5 cleared for cardiac procedures in the U.S., Europe, India, Japan, and Korea. During Q3, we received FDA 510K clearance on Da Vinci 5 for surgeon-initiated tool eject and multi-arm targeting, both of which bring incremental efficiency and surgeon autonomy to procedures.

Surgeons have reported that these innovations innovations support extending access to DaVinci surgery beyond traditional workdays and hours. Recently, we submitted a cavitational ultrasonic aspirator instrument for FDA 510K clearance for use in liver and pancreas procedures. And last week, we received FDA
510K clearance for an integrated version ?of the DaVinci 5 handheld endoscope. In August, we received FDA 510K clearance for our foundational non-commercial next-generation flexible robotic endoscope system for use in the gastrointestinal tract.

This program is early in its development, but we are encouraged by our progress and look
forward to updating ?you as we advance. Adoption of intuitive telepresence continues to increase with surgeons using these sessions to share techniques and to scale training in ways that were not previously practical. Telepresence on DaVinci 5 serves as a foundation for our efforts in telesurgery, where we expect several regulatory clearances in the first half of 2028.

Our teams continue to develop additional digital and AI capabilities on DaVinci 5, including a voice activated user interface and automated fourth arm control to further enhance efficiency and the user experience. AI controlled motion and surgery has the
potential to improve efficiency in outcomes, ?but it is early and must earn the confidence of regulators, surgeons, care teams, and patients before we deploy it at scale.

Looking ahead, our objective at Intuitive is to reach more patients with the best care available by combining robotics, human expertise, data, and artificial intelligence
so that minimally invasive care becomes more accessible and less variable. The problems we are working to address are significant and specific. Minimally invasive surgery access and adoption remain uneven around the world. Patients wait too long between detection and treatment, and the care a patient receives still varies more than it should, depending on the hospital they enter and the surgeon available that ?day.

Over time, we are focused on significantly advancing the quintupillane to ensure that the broader patient journey can become more predictable, more connected, and less disruptive to a patient's
?life. Before I pass the time to Jamie, today we announced that we have reached an agreement, subject to court approval, with U.S. customers who participated in the class action lawsuit on third-party remanufacturing of DaVinci Instruments and third party servicing of DaVinci systems.

We believe that this no-fault
settlement provides certainty for both our customers and intuitive and maintains our ability to advance the safety, quality, and security of our products. And with that, I'll turn the time over to Jamie to take you through our finances in greater detail. Good

Passages & reports (69)
  • Good afternoon, and thank you for joining us today. Q3 was a strong quarter for Intuitive,…
  • procedures.
  • In
  • the U.S., DaVinci procedure growth was 10%, and outside the U.S., DaVinci procedure growth…
  • DaVinci ecosystem to provide their patients with improved
  • care.
  • That adoption has been driven by our commitment to innovation, robust training, and clinic…
  • In
  • the quarter almost 7,000 customers in more than 70 countries perform DaVinci procedures at…
  • day. On
  • the clinical evidence front, more than 48,000 peer-reviewed publications have evaluated th…
  • As
  • I described last quarter, we continue to see increasing segmentation across our customer b…
  • and
  • we have positioned Intuitive to serve current and future customers with both our existing …
  • In
  • Q3, global customer demand across our DaVinci portfolio remains strong. DaVinci system pla…
  • with
  • DaVinci 5 and SP accounting for 65% of global placements. Installations of XIR and X more …
  • DaVinci 5 systems installed worldwide, used by over 18,000 surgeons since launch.
  • We
  • continue to see strong interest in XIR, both in the U.S. and internationally, where custom…
  • Our
  • DaVinci Single Port platform is playing an increasingly important role for our customers a…
  • and
  • in Q4, we plan to make a U.S. submission
  • for
  • the SP vessel sealer, which we believe is a key enabler for wider adoption of our SP platf…
  • capacity.
  • In
  • Q3, we finalized a set of pricing actions for a subset of high-volume benign procedures wh…
  • and
  • enable DaVinci technology to reach more patients around the world. Jamie will describe the…
  • to
  • help customers establish and expand their DaVinci programs.
  • As
  • of Q3, nearly 4,000 international customers
  • have
  • a DaVinci program, and nearly 25% operate two or more systems. These customers are moving …
  • and
  • inguinal hernia repair in Japan. To support this growth, we are continuing to build the fo…
  • with broad-based global demand. In Europe, Germany led the region with 20 system installat…
  • while India had another strong quarter with 42% procedure growth, surpassing 200,000 cumul…
  • facility
  • in
  • Penang, Malaysia. We expect this facility to begin operations in 2028. Beyond DaVinci, we …
  • we received reimbursement for Ion in Korea, and we expect further reimbursement actions in…
  • and
  • cardiac procedures on DaVinci 5, as well as transvaginal gynecological procedures on SP.
  • We
  • now have DaVinci 5 cleared for cardiac procedures in the U.S., Europe, India, Japan, and K…
  • to procedures. Surgeons have reported that these innovations innovations support extending…
  • 510K clearance for an integrated version
  • of
  • the DaVinci 5 handheld endoscope. In August, we received FDA 510K clearance for our founda…
  • forward to updating
  • you
  • as we advance. Adoption of intuitive telepresence continues to increase with surgeons usin…
  • regulatory clearances in the first half of 2028. Our teams continue to develop additional …
  • potential to improve efficiency in outcomes,
  • but
  • it is early and must earn the confidence of regulators, surgeons, care teams, and patients…
  • so that minimally invasive care becomes more accessible and less variable. The problems we…
  • depending on the hospital they enter and the surgeon available that
  • day.
  • Over time, we are focused on significantly advancing the quintupillane to ensure that the …
  • life.
  • Before I pass the time to Jamie, today we announced that we have reached an agreement, sub…
  • settlement provides certainty for both our customers and intuitive and maintains our abili…

Speaker 3

Unverified voice label

afternoon. I'll describe our performance on a non-gap basis ?and I'll summarize our GAAP results later in my remarks. ?A reconciliation between our non-gap and gap results is available on our website. ?The strength of our financial performance this quarter reflects the durability of our business model, driven by an expanding portfolio of differentiated products that provide clear clinical and economic value for our customers and their patients.

Increasingly, our DaVincian Ion Systems
?and the intuitive ecosystem are being integrated into customers' core infrastructure across a variety of procedures, sites of care, and geographies, driving value for hospitals and healthcare providers and recurring revenue for intuitive. Today, we are also quantifying the instrument pricing actions we discussed in July, which we expect to reduce DaVinci INA revenue per procedure by approximately 3 to 5% ?on a mixed constant basis once fully implemented. ?

This
is a deliberate choice to broaden adoption in high volume benign procedures, ?and I will describe these actions in more detail shortly. Key financial highlights for the quarter are as follows. Revenue grew 22% to just over $3 billion, of which 84% was recurring revenue. Net DaVinci placements, that is placements that expand the installed base, grew 40%.

Passages & reports (16)
  • afternoon. I'll describe our performance on a non-gap basis
  • and
  • I'll summarize our GAAP results later in my remarks.
  • A
  • reconciliation between our non-gap and gap results is available on our website.
  • The
  • strength of our financial performance this quarter reflects the durability of our business…
  • and
  • the intuitive ecosystem are being integrated into customers' core infrastructure across a …
  • discussed in July, which we expect to reduce DaVinci INA revenue per procedure by approxim…
  • on
  • a mixed constant basis once fully implemented.
  • This
  • is a deliberate choice to broaden adoption in high volume benign procedures,
  • and
  • I will describe these actions in more detail shortly. Key financial highlights for the qua…

Speaker unclear

?Non

Passages & reports (1)
  • Non

Speaker 3

gap operating margin was 42% of revenue, or 41% excluding a one time pre-tax tariff refund of twenty-eight million dollars. ?Non gap earnings per share grew twenty-five percent to three dollars per share. Core metrics was solid in Q3, taking Da Vinci and I on together, total procedures grew 15%, the installed base of systems grew 13%, and average system utilization increased two percent. Revenue growth of twenty two percent against total procedure growth of fifteen percent reflects our innovation-led strategy and growth in system placements. ?

As
DaVinci 5, SP, and Ion become a greater proportion of our business, revenue growth benefits from a richer product mix, higher levels of integration, and incremental upgrade volumes. Additionally, the scale and cost advantages we have built allow us to broaden our platform portfolio, reach customers in more geographies, and expand access by lowering the cost of DaVinci surgery. ?The price reductions are concentrated in high volume benign procedures where cost may be a barrier to adoption.

Those procedures, particularly outside the US and in ambulatory settings, are where we see the largest opportunity to serve incremental patients. This is a strategic decision to reinvest a portion of the
value our innovation creates in lower customer costs where they will have the greatest impact on adoption. ?We believe broader adoption creates more long-term value than near term revenue per procedure. Turning to the clinical side of our business, in the US, total procedures increased 11%, reflecting 10% growth in Da Vinci procedures and 29% growth in Ion procedures.

US
DaVinci growth of 10% was consistent with the expectations we described in July and reflects in part the 16% growth in the prior year quarter, our most difficult comparison of the ?year. hours procedures and benign gynecology procedures other than hysterectomy continue to leak growth. DaVinci 5 accounted for more than a quarter of US procedures in Q3, up from 13% a year ago, ?and DaVinci 5 systems continue to run at utilization above our XI base.

Looking ahead, we believe the breadth of surgeon adoption, the continued expansion of benign general surgery,
?and a growing DaVinci 5 and SP install installed base, together with procedures earlier in adoption, including emergent general surgery, cardiac, and nipple-sparing mastectomy, positions us for durable US procedure growth over the long term. ?In the short term, we continue to monitor the impacts from lower ACA enrollment, changes to Medicaid eligibility, and potential changes to 340B.

Outside the US, total and DaVinci procedures grew 20%, with Europe up twenty percent, Asia up nineteen percent, and
rest of world geographies up twenty two percent. In Europe, growth was led by the UK, Germany, and Italy. In Asia, India and Taiwan led growth, and Japan procedure growth accelerated, reflecting early signs of a response to the June reimbursement changes. Procedure growth in China was roughly in line with the corporate average, reflecting lower recent capital placements. ?

In
rest rest of world markets, growth was led by Canada, Australia, and Brazil. Within OUS results, DaVinci adoption for benign procedures continued to accelerate, growing 41% in Q3, up from 37% in Q2 and 34% in Q1, with the strongest growth in hernia repair and colosystectomy. Benign procedures represent over a quarter of our international volume today, and the significant majority of the gap between our current international volumes and the addressable opportunity, which is why they are a focus of our investments.

As we build local clinical and
economic evidence, a growing number of customers in OUS markets are recognizing the clinical benefits of DaVinci for these procedures, and our tiered system portfolio, including XIR, together with the pricing actions I will describe shortly, provides customers the flexibility to right-size their programs relative to to local reimbursement. Third quarter SP procedure growth was 55%, reflecting accelerated growth in the US of 50% and growth of 40% in Korea, our largest SP market.

We now have 487 SP systems installed across 27
countries, and procedures in the 25 markets other than the US and Korea nearly doubled from Q3 last year. Total INA revenue in Quarter three grew 18% to $1.8 billion. DaVinci INA revenue per procedure was approximately $1,860 compared to $1,800 last year, primarily driven by higher SP procedures and DaVinci 5 specific INA, partially offset by procedure mix.

With respect to instrument pricing, there are two developments to describe. The first is a set of pricing actions we will implement beginning in the first
half of including the expansion of our extended use program announced in May. The second is a policy-driven price reduction in China that starts to take effect next month. As Dave described earlier, customer needs are increasingly segmented. In complex procedures, value comes from innovation and clinical capability. ?

In
high volume benign procedures such as cholecyssectomy and ingrinal hernia repair, it comes from reliability, efficiency and economics. and that's where our pricing actions are focused. Beginning in the first half of 2027, we will extend the useful lives of a subset of core Endorisk instruments ?on our fourth and fifth generation platforms and introduce volume based pricing. Both lower our customers' costs per procedure.

Years of investment in instrument design and manufacturing scale enable us to preserve the quality and reliability customers count
?on. In the US, the extended use instruments require a 510K clearance, which is in process. In China, ?the charge code policy changes we described last quarter will result in a significant reduction in our INA prices in that market beginning in November. We continue to engage with provincial governments on implementation ?and to progress through the green channel process for SP and DaVinci 5.

Taken together, we expect these pricing actions and the China price reduction
?to lower DaVinci INA revenue per procedure by approximately 3 to 5% ?on a mixed constant basis once fully implemented, meaning holding procedure, product, and geographic mixed constant to isolate the pricing changes themselves. For reference, that is less than the 7% we estimated when we launched our first extended use program in 2020. ?

The
accretive dynamics we described last quarter, including forced feedback adoption ?and the mixed shift toward DaVinci 5 and SP are not included and will be positive contributors to INA revenue per procedure. ?In terms of timing, the China reduction takes effect in the fourth quarter, or the extended life instruments, as part of our broader INA pricing actions will roll out by country beginning in the first half of 2027, so the remaining impact will build progressively over 2027 rather than as a step function.

Turning to cleared procedure categories that we expect to be future growth drivers, cardiac procedures grew 40% in Q3, and during the quarter, we received CE mark for use of DaVinci 5 in cardiac procedures in Europe. We now estimate that the line of sight cardiac opportunity is between 300,000 and
400,000 procedures a year in the regions we are cleared. Separately, breast surgery grew 42%.

Both remain early stage opportunities whose near-term pace is linked to the training of surgeons and the accumulation of clinical evidence, and we are investing in both. Today these procedure
volumes are still small relative to our total volume. Turning to capital performance and starting with our DaVinci business, we placed 546 DaVinci systems in quarter three, an increase of 28% compared to 427 systems in Q3 last year.

Demand was broad-based across our
platform portfolio. 315 DaVinci 5 systems, 87 XI, 65 XAR, 42 SP, and 37X systems. DaVinci 5 placements included 41 in OUS markets, up from 12 last year, as DaVinci 5 becomes available in more countries. In the US, we placed 335 systems, up 27% from the 263 systems placed last year, driven by an increased number of multi-system deals as customers continue to convert to DaVinci 5.

Building on our focus on
amuletary surgery centers, we installed 18 systems at US ASCs in Q3, including 15 XIR systems. This is an early stage multi-year effort, and placements will be uneven quarter to quarter, but our pipeline of ASC opportunities continues to build, informed by customer familiarity with XIR's capabilities and reliability, and its favorable cost profile. Outside the US, we placed 211 systems, an increase of 29% compared to the 164 systems placed last year.

By region, we placed 115 systems in Europe, up
83% from 63 last year, 78 in Asia, up 30% from 60%, and 18 in rest of world countries compared to 41 last year. Rest of world placements tend to be uneven quarter to quarter. Europe's performance reflected our broadening focus with record quarterly placements in Portugal, Turkey, and Austria, and solid growth in Poland, Croatia, and Romania.

Across all geographies, we place 37 X systems and 65 XIR systems with purchased ASPs of approximately half a million dollars and $1.2 million respectively, demonstrating our
ability and willingness to compete effectively across the broad spectrum of customers and their economic objectives. Over the last three years, we have entered new geographies, including Croatia, Peru, Morocco, and Lithuania, and in 2027 we plan to accelerate our expansion into additional countries we do not serve today.

Given increasing investments in OUS markets and planned expansion into new geographies, in January we plan to update our estimate of the long term opportunity in soft tissue surgery.
?We placed a record 42 SP systems in Q3, including 21 in the US and 12 in Korea, ?and the installed base of SP systems increased 42% from the year ago period to 487 systems. For our Ion platform, we placed 56 systems in Q3 compared to 50 systems last year.

Given our capital performance, Quarter 3 systems revenue grew
30% to $769 million.

Passages & reports (68)
  • gap operating margin was 42% of revenue, or 41% excluding a one time pre-tax tariff refund…
  • Non
  • gap earnings per share grew twenty-five percent to three dollars per share. Core metrics w…
  • Revenue growth of twenty two percent against total procedure growth of fifteen percent ref…
  • As
  • DaVinci 5, SP, and Ion become a greater proportion of our business, revenue growth benefit…
  • in more geographies, and expand access by lowering the cost of DaVinci surgery.
  • The
  • price reductions are concentrated in high volume benign procedures where cost may be a bar…
  • value our innovation creates in lower customer costs where they will have the greatest imp…
  • We
  • believe broader adoption creates more long-term value than near term revenue per procedure…
  • DaVinci growth of 10% was consistent with the expectations we described in July and reflec…
  • year.
  • hours procedures and benign gynecology procedures other than hysterectomy continue to leak…
  • and
  • DaVinci 5 systems continue to run at utilization above our XI base. Looking ahead, we beli…
  • and
  • a growing DaVinci 5 and SP install installed base, together with procedures earlier in ado…
  • In
  • the short term, we continue to monitor the impacts from lower ACA enrollment, changes to M…
  • rest of world geographies up twenty two percent. In Europe, growth was led by the UK, Germ…
  • roughly in line with the corporate average, reflecting lower recent capital placements.
  • In
  • rest rest of world markets, growth was led by Canada, Australia, and Brazil. Within OUS re…
  • repair and colosystectomy. Benign procedures represent over a quarter of our international…
  • economic evidence, a growing number of customers in OUS markets are recognizing the clinic…
  • relative to to local reimbursement. Third quarter SP procedure growth was 55%, reflecting …
  • countries, and procedures in the 25 markets other than the US and Korea nearly doubled fro…
  • compared to $1,800 last year, primarily driven by higher SP procedures and DaVinci 5 speci…
  • half of including the expansion of our extended use program announced in May. The second i…
  • innovation and clinical capability.
  • In
  • high volume benign procedures such as cholecyssectomy and ingrinal hernia repair, it comes…
  • on
  • our fourth and fifth generation platforms and introduce volume based pricing. Both lower o…
  • on.
  • In the US, the extended use instruments require a 510K clearance, which is in process. In …
  • the
  • charge code policy changes we described last quarter will result in a significant reductio…
  • and
  • to progress through the green channel process for SP and DaVinci 5. Taken together, we exp…
  • to
  • lower DaVinci INA revenue per procedure by approximately 3 to 5%
  • on
  • a mixed constant basis once fully implemented, meaning holding procedure, product, and geo…
  • The
  • accretive dynamics we described last quarter, including forced feedback adoption
  • and
  • the mixed shift toward DaVinci 5 and SP are not included and will be positive contributors…
  • In
  • terms of timing, the China reduction takes effect in the fourth quarter, or the extended l…
  • Turning to cleared procedure categories that we expect to be future growth drivers, cardia…
  • 400,000 procedures a year in the regions we are cleared. Separately, breast surgery grew 4…
  • volumes are still small relative to our total volume. Turning to capital performance and s…
  • platform portfolio. 315 DaVinci 5 systems, 87 XI, 65 XAR, 42 SP, and 37X systems. DaVinci …
  • in more countries. In the US, we placed 335 systems, up 27% from the 263 systems placed la…
  • amuletary surgery centers, we installed 18 systems at US ASCs in Q3, including 15 XIR syst…
  • XIR's capabilities and reliability, and its favorable cost profile. Outside the US, we pla…
  • 83% from 63 last year, 78 in Asia, up 30% from 60%, and 18 in rest of world countries comp…
  • placements in Portugal, Turkey, and Austria, and solid growth in Poland, Croatia, and Roma…
  • ability and willingness to compete effectively across the broad spectrum of customers and …
  • countries we do not serve today. Given increasing investments in OUS markets and planned e…
  • We
  • placed a record 42 SP systems in Q3, including 21 in the US and 12 in Korea,
  • and
  • the installed base of SP systems increased 42% from the year ago period to 487 systems. Fo…
  • 30% to $769 million.

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 3

average selling price for purchase DaVinci Systems was approximately $1.6 million, flat to last year, as a higher mix of DaVinci 5 was primarily offset by a higher mix of XIRs. Quarter 3 service revenue increased 22% to $482 million, reflecting the increased install base of DaVinci and Ion Systems and a higher mix of DaVinci 5. Turning now to the rest of the PL, non-GAP gross margin for the quarter was 69.9%, an increase from 68% in Q3 of last year.

Q3 results included a one-time benefit of $28 million
?from the refund of previously paid IEPA tariffs. Excluding this benefit, non-gap gross margin would have been 68.9%, an improvement of 90 basis points year over year. ?The underlying improvement primarily reflects product cost reductions and fixed overhead leverage, and our engineering and operations teams continue to execute on cost reduction programs across each of our platforms.

Quarter three non-gap operating expenses increased 18% year over year, driven by increased
variable compensation reflecting our results, higher headcount, and higher prototype expenses as several programs advanced in development. RD again grew faster than SGA. A portion of the increase reflects the timing of expenses between quarters. Given the progress our RD teams are making ?and the opportunities in front of us, we will continue to prioritize incremental investment in our existing and new platforms and in advancing our AI capabilities, which we believe will meaningfully differentiate our solutions and expand the number of patients we can serve.

Non-gap other income was $75 million for the
quarter compared to $83 million last quarter, reflecting lower average cash balances following our share repurchases. Our non-gap effective tax rate for the quarter for quarter three was 21.4%, consistent with our expectations. Now turning to our gap results, ?gap net income for the quarter was $523 million or $1.49 per share compared to $704 million or $1.95 per share in Q3 of last year.

Our gap results reflect the $450 million litigation settlement that Dave described earlier. This settlement is subject to court approval, and
we do not expect that decision until next ?year. We ended the quarter with $6.8 billion in cash and investments down from $8.6 billion last quarter. Cash generated from operating activities was more than offset by stock repurchases of $2.9 billion at an average price of $377 per share and capital expenditures of $113 million.

With that, I'll turn it over to Jamie to discuss recent clinical publications. Thank you, Jamie. It's a pleasure

Passages & reports (16)
  • average selling price for purchase DaVinci Systems was approximately $1.6 million, flat to…
  • base of DaVinci and Ion Systems and a higher mix of DaVinci 5. Turning now to the rest of …
  • from
  • the refund of previously paid IEPA tariffs. Excluding this benefit, non-gap gross margin w…
  • The
  • underlying improvement primarily reflects product cost reductions and fixed overhead lever…
  • variable compensation reflecting our results, higher headcount, and higher prototype expen…
  • and
  • the opportunities in front of us, we will continue to prioritize incremental investment in…
  • quarter compared to $83 million last quarter, reflecting lower average cash balances follo…
  • gap
  • net income for the quarter was $523 million or $1.49 per share compared to $704 million or…
  • we do not expect that decision until next
  • year.
  • We ended the quarter with $6.8 billion in cash and investments down from $8.6 billion last…
  • With that, I'll turn it over to Jamie to discuss recent clinical publications. Thank you, …

Speaker 4

Unverified voice label

to speak with you this ?afternoon. As we routinely do on these calls, I'd like to share with you recently published peer-reviewed literature that we found to be notable. ?In addition to the specific data highlighted on this call, we encourage you to consider this data alongside the wider body of evidence detailing these topics and others in published scientific studies over the years. ?On our Q4 2024 earnings call, ?we describe the landmark compare study, ?a meta-analysis where the authors reported multiple benefits for the DaVinci approach when compared to alternative minimally invasive or open approaches in commonly performed oncologic procedures.

Last month, Dr. Thomas Shinn and colleagues from the Massachusetts General Brigham and the University of Virginia School of Medicine, in collaboration
with researchers from Intuitive, published the Benign Compare Study, comparing perioperative outcomes of benign, minimally invasive, laparoscopic, DaVinci Robonic, and Open Procedures, a systematic review and meta-analysis of evidence and analysis surgery open. This benign compare study looked primarily at standard perioperative and 30-day clinical outcomes of thirteen high volume benign procedures across general surgery, gynecology, urology, and bariatrics, including but not limited to benign hysterectomy, cholicystectomy, benign colon, and various hernia repairs. ?

In
many of these procedures, conventional laparoscopy has long been the standard of ?care. This meta-analysis included data from 366 studies across 32 countries, published between 2010 and 2024, ?and included randomized controlled trials, prospective and retrospective cohort studies, and large real-world database studies. In total, ?the analysis covered roughly 1.5 million Da Vinci patients, 10.7 million laparoscopic patients, and 1.7 million open patients. Results identified lower conversions to open surgery as the most clinically important and consistent finding.

Compared with laparoscopy, DaVinci procedures were associated with
54% lower odds of conversion, with significant reductions observed in benign hysterectomy, ventral and inguinal hernia repair, myomectomy, polysystectomy, and benign colon surgery. ?As the authors noted, conversion to open surgery is is an important interoperative event associated with increased morbidity and prolonged hospitalization, which has negative implications for patients and healthcare systems. DaVinci patients also had 13% lower odds of blood transfusion ?and a shorter length of stay than laparoscopic patients, with the largest reductions in benign colon surgery, adrenalectomy, and benign hysterectomy.

Rates of 30 day complications, readmissions, and mortality
?were comparable between DaVinci and laparoscopy, while average DaVinci operative time were about 24 minutes longer. Compared with open surgery, DaVinci was associated with larger differences across nearly every studied measure, including 46% lower odds of postoperative complications and hospital stays that were nearly two days shorter. These differences have positive implications for patients and healthcare systems. ?

The
authors concluded that DaVinci was associated with fewer conversions, less pain, and faster recovery compared with open and laparoscopic surgery, supporting its effectiveness for benign indications. From my perspective as a surgeon, this large scale analysis of millions of patients provides meaningful data on the expanding use of Da Vinci surgery beyond oncology. These clinical correlations point toward a compelling value proposition for the use of DaVinci in these commonly performed high volume benign procedures.

With that, I'll pass the time over to Dan.

Passages & reports (33)
  • to speak with you this
  • afternoon. As we
  • routinely do on these calls, I'd like to share with you recently published peer-reviewed l…
  • In
  • addition to the specific data highlighted on this call, we encourage you to consider this …
  • On
  • our Q4 2024 earnings call,
  • we
  • describe the landmark compare study,
  • a
  • meta-analysis where the authors reported multiple benefits for the DaVinci approach when c…
  • with researchers from Intuitive, published the Benign Compare Study, comparing perioperati…
  • primarily at standard perioperative and 30-day clinical outcomes of thirteen high volume b…
  • repairs.
  • In
  • many of these procedures, conventional laparoscopy has long been the standard of
  • care.
  • This meta-analysis included data from 366 studies across 32 countries, published between 2…
  • and
  • included randomized controlled trials, prospective and retrospective cohort studies, and l…
  • the
  • analysis covered roughly 1.5 million Da Vinci patients, 10.7 million laparoscopic patients…
  • 54% lower odds of conversion, with significant reductions observed in benign hysterectomy,…
  • As
  • the authors noted, conversion to open surgery is is an important interoperative event asso…
  • and
  • a shorter length of stay than laparoscopic patients, with the largest reductions in benign…
  • were
  • comparable between DaVinci and laparoscopy, while average DaVinci operative time were abou…
  • shorter. These differences have positive implications for patients and healthcare systems.
  • The
  • authors concluded that DaVinci was associated with fewer conversions, less pain, and faste…
  • These clinical correlations point toward a compelling value proposition for the use of DaV…

Speaker 1

Thank you, Jamie. Our updated financial outlook for 2026 is as follows starting with DaVinci procedures. In July, we forecast full year 2026 procedure growth to be within a range of 13.5% to 15.5%, with an expectation to be closer to the midpoint. ?We are narrowing our forecast to be within a range of 14% to 15%, with an expectation to be closer to the midpoint.

Our range continues to consider the impact of changes to ACA premium subsidies on patient behavior in the U.S., as well as tender volumes and competitive intensity in China, among other factors.
Turning to gross profit, on our last call, we forecast non GAP gross profit margin to be within a range of 68 and 69% of revenue, including an estimated 100 basis point impact from tariffs as well as related refunds.

We are updating our estimate to be within a range of 68.7% and
69.3% of revenue, including an estimated 90 basis points impact from tariffs as well as related refunds. Factors impacting the range include faster growth of newer products in DaVinci 5 and Ion, partially offset by product cost reductions. We continue to forecast higher input costs in certain areas like freight and semiconductor memory.

Our actual non GAP gross profit margin will vary depending largely on product, regional and trade in mix, and pricing. For operating expenses, we continue to expect 2026 non GAAP operating expense growth of 11% to
13%. As a reminder, in Q4 2025, ?we made a $70 million multi-year contribution to the Intuitive Foundation. We do not expect to make a contribution to the Foundation in 2026.

Throughout the year, and in Q3 in particular, we grew RD at a rate above SGA. We expect that trend to continue over the remainder of
the ?year. We now estimate non-cash stock compensation expense between $860 and $870 million. We now forecast non-gap other income, which is comprised mostly of interest income, of between $300 and $310 million due primarily to the impact of share repurchase activity in Q3.

With regard to income tax, we expect our non-GAP effective tax rate in Q4 to be 22%, plus or minus 50 basis points. That concludes our prepared remarks. As we open the line to your questions, we ask that you limit yourselves to one question so that we may reach as many analysts as possible.

Passages & reports (13)
  • Thank you, Jamie. Our updated financial outlook for 2026 is as follows starting with DaVin…
  • We
  • are narrowing our forecast to be within a range of 14% to 15%, with an expectation to be c…
  • Turning to gross profit, on our last call, we forecast non GAP gross profit margin to be w…
  • 69.3% of revenue, including an estimated 90 basis points impact from tariffs as well as re…
  • certain areas like freight and semiconductor memory. Our actual non GAP gross profit margi…
  • 13%. As a reminder, in Q4 2025,
  • we
  • made a $70 million multi-year contribution to the Intuitive Foundation. We do not expect t…
  • the
  • year.
  • We now estimate non-cash stock compensation expense between $860 and $870 million. We now …
  • With regard to income tax, we expect our non-GAP effective tax rate in Q4 to be 22%, plus …

Speaker 0

Thank ?you. Ladies and gentlemen, as a reminder to ask the question, please press star 1 1 on your telephone, then wait for your name to be announced. To withdraw your question, please press star 1 1 again. Please stand by while we compile the QA roster.

Passages & reports (3)
  • Thank
  • you.
  • Ladies and gentlemen, as a reminder to ask the question, please press star 1 1 on your tel…

Questions & answers

Speaker 0

Our first question comes from the line of Lawrence Beagleson with Wells Fargo. Your line is open.

Passages & reports (1)
  • Our first question comes from the line of Lawrence Beagleson with Wells Fargo. Your line i…

Speaker unclear

?Good afternoon. Thanks for taking the question. I'll just keep it at one

Passages & reports (1)
  • Good afternoon. Thanks for taking the question. I'll just keep it at one

Speaker 5

Unverified voice label

here, focused on U.S. procedure growth. ?So uh Jamie or or Dave, U.S. uh DaVinci procedure growth was stable, you know, on a stack two-year basis, but you know, the 10% growth in the quarter was the the lowest we've seen uh since COVID. Uh shipments were strong, uh, and it sounds like you have a ton of innovation ?uh and the extended use program is coming.

So are we seeing a temporary lull in U.S. DaVinci procedure growth and the innovations and the pricing actions will help accelerate U.S. DaVinci procedures as soon as next year? I'd love any any color on that. Thank

Passages & reports (5)
  • here, focused on U.S. procedure growth.
  • So
  • uh Jamie or or Dave, U.S. uh DaVinci procedure growth was stable, you know, on a stack two…
  • uh
  • and the extended use program is coming. So are we seeing a temporary lull in U.S. DaVinci …

Speaker unclear

?you. Yeah,

Passages & reports (1)
  • you. Yeah,

Speaker 2

hey Larry, this is Dave, and I appreciate the question. Let me uh frame up the US opportunity a bit and

Passages & reports (1)
  • hey Larry, this is Dave, and I appreciate the question. Let me uh frame up the US opportun…

Speaker 3

then uh you

Passages & reports (1)
  • then uh you

Speaker 2

know Jamie can dive in with some specifics. So uh for me, the U.S. opportunity really breaks down into two areas. The first is about the addressable opportunity right in front of us that we're going after on a daily basis. And the second is a longer term opportunity to expand the indications that Da Vinci can have an impact in. And so if we look at the first part for the procedures that we know where the U.S.

procedure opportunity is significant, particularly in benign general surgery. When I'm talking to customers, in order for them to
adopt robotics across the benign general surgery areas as well as other benign indications, they really want to see how it compares to the alternatives. Where laparoscopy is well entrenched like Jamie described, and against open surgeries sometimes. They want to see how's it doing clinically, how's it doing economically?

Passages & reports (3)
  • know Jamie can dive in with some specifics. So uh for me, the U.S. opportunity really brea…
  • expand the indications that Da Vinci can have an impact in. And so if we look at the first…
  • adopt robotics across the benign general surgery areas as well as other benign indications…

And that is something we've invested in for a long time. We've worked hard to provide customers the data that they need from Intuitive, combine it with their data so they can understand how those uh modalities are doing against each ?other. In Q3, I had the opportunity actually to meet with about five large IDN customers. And when I was meeting with them, what what I'm seeing is now they are developing their own real time dashboards looking at the economics and the clinical outcomes relative of DaVinci relative to laparoscopy and open.

And I think that's a that's a shift that I believe is worth noting because it's moving from anecdotes and sort of episodic data that they may look at once a year and they're looking at it on a routine basis. And so when I saw those data and talked to those
customers, robotics is comparing favorably as compared to the other modalities. And so you take that that sort of foundation of data you get directional data from studies like Compare, but you get the actual data in our customers' hand through these interactions like I'm describing.

Passages & reports (5)
  • And that is something we've invested in for a long time. We've worked hard to provide cust…
  • other.
  • In Q3, I had the opportunity actually to meet with about five large IDN customers. And whe…
  • laparoscopy and open. And I think that's a that's a shift that I believe is worth noting b…
  • customers, robotics is comparing favorably as compared to the other modalities. And so you…

Combine that with our portfolio, the rest of our ecosystem, with the commercial performance of our capital teams, expanding capacity, with the focus of our commercial teams broadly, clinical service training, and in the pricing actions that Jamie described. And I think that that's the foundation of uh durable US procedure growth into that significant opportunity.

Passages & reports (2)
  • Combine that with our portfolio, the rest of our ecosystem, with the commercial performanc…
  • think that that's the foundation of uh durable US procedure growth into that significant o…

Speaker 3

Lar Larry, I might just add um the way we think about it, the the unit opportunity in front of us in the US is significant. I understand ?uh investor intention on the US kind of growth over the last several quarters. ?Um there's four things that we're focused on that we're driving, maybe just to add some colour. First is adding capacity, particularly to support the benign general surgery growth.

And what you saw in this quarter was US net placements increased forty-one percent,
?and that's a little bit of a change from what we've seen in in more recent quarters. Second thing is, as we've talked about, we've um more recently added a focus on the ASC opportunity. If you look at the number of systems we've placed in ASCs last two quarters combined, that's more than we've placed in ASCs in almost the last three years, and we think that continues to be a an attractive opportunity for us.

And those first two areas are supported by both the INA pricing actions that we've described and our tier portfolio. If you want to invest in DaVinci 5 in the hospital with its capability,
with a capability that will only grow every year as we do software updates and extend the ecosystem, that's a good investment. But our tier portfolio offers those customers an XIR in a HFPD or an ASC.

The other two areas that we're driving, we're focused on over longer horizons.

Passages & reports (9)
  • Lar Larry, I might just add um the way we think about it, the the unit opportunity in fron…
  • uh
  • investor intention on the US kind of growth over the last several quarters.
  • Um
  • there's four things that we're focused on that we're driving, maybe just to add some colou…
  • and
  • that's a little bit of a change from what we've seen in in more recent quarters. Second th…
  • in ASCs in almost the last three years, and we think that continues to be a an attractive …
  • with a capability that will only grow every year as we do software updates and extend the …

Three is to um ?kind of progress cardiac and breast along the early stage adoption curve it's in, and that requires both investment and execution. ?And then the fourth is what Dave described. We have programs today in R D that have the potential to add new um indications in the US and elsewhere, and those are moving along and progressing, and and and those are quite interesting.

Again, they're on longer longer term horizons.

Passages & reports (5)
  • Three is to um
  • kind
  • of progress cardiac and breast along the early stage adoption curve it's in, and that requ…
  • And
  • then the fourth is what Dave described. We have programs today in R D that have the potent…

Speaker 0

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Our next question comes from the line of Robert Marcus, the JP Morgan. Your line is open.

Passages & reports (1)
  • Our next question comes from the line of Robert Marcus, the JP Morgan. Your line is open.

Speaker 5

Oh great. Uh

Passages & reports (1)
  • Oh great. Uh

Speaker unclear

?thank you for taking the

Passages & reports (1)
  • thank you for taking the

Speaker 6

Unverified voice label

question. Um I want to follow ?up on the extended use and and it's great. I appreciate the uh three to five percent headwind over the uh the total enactment period both between that and uh uh the China uh pricing how do we think about necessarily the timelines? Will there be any stocking ahead of the implementation of this? And how do we think about it down the PL uh both from a gross and operating margin?

If I could add one more there. Last program you did have a uh price elasticity benefit on on volumes. How are you thinking about
volumes uh in response to

Passages & reports (5)
  • question. Um I want to follow
  • up
  • on the extended use and and it's great. I appreciate the uh three to five percent headwind…
  • there be any stocking ahead of the implementation of this? And how do we think about it do…
  • volumes uh in response to

Speaker unclear

?You're

Passages & reports (1)
  • You're

Speaker 4

probably gonna have to remind me of your questions, Robbie, as I go along. But um there there may well be a little bit of stocking kind of customer ordering pattern volatility uh across the period in which we launch. Um I wouldn't expect that at this point to be significant, and obviously we'll we'll call that out as that occurs. Um in terms ?of the impact on uh gross margin, I would say that it would be a modest impact on gross margin that will look across twenty seven to offset with the cost reduction programs that we have in play.

Um and therefore,
?you know, whatever impact there is on gross margin can um fall through to to operating margin, but I expect that to be small and and and offset at some point in the year. Um with respect to elasticity, I I would just say um we believe that these actions will drive elasticity. That's the underlying intention, because um where we're applying them to the greatest extent is is where there are cost sensitivity or cost as a barrier to adoption.

And the the benefit for those high volume benign procedures is quite a bit greater than the blended three to five percent. Obviously, that's our our intention.

Passages & reports (7)
  • probably gonna have to remind me of your questions, Robbie, as I go along. But um there th…
  • call that out as that occurs. Um in terms
  • of
  • the impact on uh gross margin, I would say that it would be a modest impact on gross margi…
  • you
  • know, whatever impact there is on gross margin can um fall through to to operating margin,…
  • intention, because um where we're applying them to the greatest extent is is where there a…

We have have looked back at the first EUP program that we did in twenty twenty, and our and our data supports the existence of elasticity, and we have confidence that that implementation

Passages & reports (1)
  • We have have looked back at the first EUP program that we did in twenty twenty, and our an…

Speaker 3

was was successful. That of course is looking at our own data but also getting feedback from from our customers. ?Um and so uh over time as we address economics ?um and you think about how we frame our line of sight opportunities as we as we address

Passages & reports (5)
  • was was successful. That of course is looking at our own data but also getting feedback fr…
  • Um
  • and so uh over time as we address economics
  • um
  • and you think about how we frame our line of sight opportunities as we as we address

Speaker 4

economics and bring costs down we expect to increase the addressable market for intuitive and so th those are the underlying intents. ?But I think um I think we have relative confidence in the elasticity. That that doesn't obviously turn on immediately in 2027, but over time.

Passages & reports (3)
  • economics and bring costs down we expect to increase the addressable market for intuitive …
  • But
  • I think um I think we have relative confidence in the elasticity. That that doesn't obviou…

Speaker 2

You know, I I know that pricing, you know, is a is a focus of the question as it relates to benign procedures and addressable opportunity. But I I also I want to make sure that we are recognizing the value of our entire portfolio. ?And so DaVinci Five and its innovation, we're pricing such that uh innovation is correlated to the value it creates.

And so we have that thrust and that focus in our portfolio while actively doing the lowering of costs that Jamie described, because that's where broader access matters.
And so it's not ?a trade-off, it's our strategy to really expand our addressable market and serve more patients around the globe. And we're uh we're confident that it's going to make a difference as we look forward.

Passages & reports (6)
  • You know, I I know that pricing, you know, is a is a focus of the question as it relates t…
  • And
  • so DaVinci Five and its innovation, we're pricing such that uh innovation is correlated to…
  • And so it's not
  • a
  • trade-off, it's our strategy to really expand our addressable market and serve more patien…

Speaker 0

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Our next question comes from the line of Travis Steve with the Bank of America. Yelan is open.

Passages & reports (1)
  • Our next question comes from the line of Travis Steve with the Bank of America. Yelan is o…

Speaker 4

Hey,

Passages & reports (1)
  • Hey,

Speaker unclear

?thanks for the question. Uh

Passages & reports (1)
  • thanks for the question. Uh

Speaker 4

maybe just a pipeline question,

Passages & reports (1)
  • maybe just a pipeline question,

Speaker unclear

?especially with uh this quarter being probably the biggest quarterly

Passages & reports (1)
  • especially with uh this quarter being probably the biggest quarterly

Speaker 6

buyback you've ever done. Um so congrats on that. May

Passages & reports (1)
  • buyback you've ever done. Um so congrats on that. May

Speaker unclear

?well there's a lot of

Passages & reports (1)
  • well there's a lot of

Speaker 6

focus ?on US procedures and you know, one of the things I've thought about is, ?you know, there ?are things that in the pipeline that can add revenue for procedure. And you know, as we're looking at the pipeline, I don't know if there's anything you'd like to to point to or what could be coming on, you know, AI use cases or imaging things or even anything that's interesting on the GI GI robot or lung cancer that that could be helpful for

Passages & reports (8)
  • focus
  • on US
  • procedures and you know, one of the things I've thought about is,
  • you
  • know, there
  • are
  • things that in the pipeline that can add revenue for procedure. And you know, as we're loo…
  • robot or lung cancer that that could be helpful for

Speaker unclear

?investors at this point.

Passages & reports (1)
  • investors at this point.

Speaker 2

Yeah, thanks, Travis. Uh it's a great point, and one that we've described a couple of times in previous quarters. You know, starting uh maybe with Ion, actually, the two active development programs that we have uh that are progressing strongly. One is around a ROSE system, and that's uh on site cytology so that the physician and the care team can understand if they the cells may be cancer or not real time, and so they can get better answers than they do today and do it more quickly.

And the second program there is endobronchial ultrasound integrated into the
ion platform. And so that allows us to do staging. Both of those should be and bring value to the ion program, ?you know, speed up the time we think from detection to diagnosis and ultimately treatment, but will be accretive to the revenue per case on the Ion platform. You mentioned vision is another area that we're very excited about when it comes to DaVinci.

And so we have multiple programs going there
with advanced visualization technology around hyperspectral imaging, fluorescing molecules, and some AI features that we do think will bring that incremental value, and we're going to be able ?to add some revenue per procedure as a result. And so it is exactly my point of this is where innovation can bring outsized value to the customer and then bring some agreed of revenue on a per procedure basis to intuitive.

And we have that across our portfolio.

Passages & reports (8)
  • Yeah, thanks, Travis. Uh it's a great point, and one that we've described a couple of time…
  • on site cytology so that the physician and the care team can understand if they the cells …
  • ion platform. And so that allows us to do staging. Both of those should be and bring value…
  • you
  • know, speed up the time we think from detection to diagnosis and ultimately treatment, but…
  • with advanced visualization technology around hyperspectral imaging, fluorescing molecules…
  • to
  • add some revenue per procedure as a result. And so it is exactly my point of this is where…

Speaker 0

Thank ?you. Please stand by for our next question.

Passages & reports (3)
  • Thank
  • you.
  • Please stand by for our next question.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from the line of Rick Wise with CEFO. Your line is open.

Passages & reports (1)
  • next question comes from the line of Rick Wise with CEFO. Your line is open.

Speaker unclear

?Good

Passages & reports (1)
  • Good

Speaker 7

Unverified voice label

afternoon. Hi Dave. Hi Jamie.

Passages & reports (1)
  • afternoon. Hi Dave. Hi Jamie.

Another question about the ASC opportunity. Can you talk ?about your progress and what's next and maybe frame the contribution to future growth and how the these next generation extended use uh uh uh uh uh approach maybe uh impacts the opportunity but related to that maybe you can touch on now just with the uh striker CMR news, we ?have two competitors likely offering uh modular systems in the ASC.

Um how do the competitive dynamics play in there? Does intuitive need a modular offering of some kind? And just help us think through those those uh various points. Thank

Passages & reports (6)
  • Another question about the ASC opportunity. Can you talk
  • about
  • your progress and what's next and maybe frame the contribution to future growth and how th…
  • CMR news, we
  • have
  • two competitors likely offering uh modular systems in the ASC. Um how do the competitive d…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

I appreciate the ?the question, Rick. And uh maybe I'll break it down into kind of two parts because one is around the ASCs, and again, we've described this before. If you talk to ASC customers, what they're asking for is not a particular architecture. What they're asking ?for is something that can be repeatable, easy to learn, easy to use, reliable, and serve the procedures that they're targeting for the ASCs in a very consistent way because it's about volume and it's about getting patients out in a repeatable, knowable way.

So if you use that as
the problem to be solved in the ASC environment, now you can start saying what kind of technology matches that and best serves that problem or solves the problem to be solved? And so if you look at how might customers look at uh robotic competitors and make a choice, and for me it comes down to basically three areas.

One is it's got to be the right architecture uh for the ASC, it's gotta be um have the right portfolio of systems so that it can be priced in a manner that fits their economics. You've got to have that broader ecosystem because we know
that's what leads to good outcomes. And then you have to have the supporting infrastructure, all the teams and capabilities that are are required to make sure a program uh runs at pace.

And so uh customers understand this, they're now looking across um potentially multiple
solutions, and they're they understand that it takes more than a robot, it does take an ecosystem, but the robot is front and center. And so you asked about the architectures. And if I look back over our 30 years, we have engineered and tested just about every form of architecture there is out there.

And that includes modular, table mounted, and other types of robots. We brought in customers to assess them and to evaluate them side by side with us. And we continue to believe that a cart-based architecture can consistent with DaVinci is the best option, is the best balance of
capability and usability, no matter where you look. And it might be in the main OR or in the ASC environment.

And so if you if we believe that it is not required to have a modular type of architecture to serve the needs of the customer in these segments, where they are doing benign
procedures and maybe increasingly complex procedures over ?time. And so I think we are well positioned with our portfolio, the pricing that Jamie described to serve the needs of our customers there.

And we look forward to earning their first choice.

Passages & reports (14)
  • I appreciate the
  • the
  • question, Rick. And uh maybe I'll break it down into kind of two parts because one is arou…
  • for
  • is something that can be repeatable, easy to learn, easy to use, reliable, and serve the p…
  • the problem to be solved in the ASC environment, now you can start saying what kind of tec…
  • for me it comes down to basically three areas. One is it's got to be the right architectur…
  • that's what leads to good outcomes. And then you have to have the supporting infrastructur…
  • solutions, and they're they understand that it takes more than a robot, it does take an ec…
  • there. And that includes modular, table mounted, and other types of robots. We brought in …
  • capability and usability, no matter where you look. And it might be in the main OR or in t…
  • procedures and maybe increasingly complex procedures over
  • time.
  • And so I think we are well positioned with our portfolio, the pricing that Jamie described…

Speaker 4

These are a bit lagged, ?but we think a little under 10% of the uh US soft tissue surgery business is in ASCs today. That's growing. About 70% of those volumes are AS are ASCs associated with or affiliated with existing IDNs? So they are customers and surgeons that we know. That's our initial focus. Our penetration of kind of all of the ASC opportunity is low in the first quartile.

And that's why now that we have XIR and we have the supply for XIR, it's a focus of

Passages & reports (4)
  • These are a bit lagged,
  • but
  • we think a little under 10% of the uh US soft tissue surgery business is in ASCs today. Th…
  • we know. That's our initial focus. Our penetration of kind of all of the ASC opportunity i…

Speaker unclear

?ours.

Passages & reports (1)
  • ours.

Speaker 0

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Our next question comes from the line of Adam Nader with Piper Sandler. Yelan is open.

Passages & reports (1)
  • Our next question comes from the line of Adam Nader with Piper Sandler. Yelan is open.

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 7

good afternoon.

Passages & reports (1)
  • good afternoon.

Speaker unclear

?Thank you for taking the question.

Passages & reports (1)
  • Thank you for taking the question.

Speaker 7

I

Passages & reports (1)
  • I

Speaker unclear

?wanted to ask about EUP 2.0 and specifically one of the

Passages & reports (1)
  • wanted to ask about EUP 2.0 and specifically one of the

Speaker 7

offsets, ?potential offsets for sensing instruments.

Passages & reports (3)
  • offsets,
  • potential offsets
  • for sensing instruments.

Speaker unclear

?And

Passages & reports (1)
  • And

Speaker 3

if I heard

Passages & reports (1)
  • if I heard

Speaker unclear

?correctly it

Passages & reports (1)
  • correctly it

Speaker 7

doesn't sound like there's any offset assumed in the ?300 to 500 basis point headwind for these. So would love just any update on for sensing instrumentation.

Passages & reports (3)
  • doesn't sound like there's any offset assumed in the
  • 300
  • to 500 basis point headwind for these. So would love just any update on for sensing instru…

Speaker 7

and how do you think it could evolve over time? And ?would also just appreciate any color in terms of kind of primary use cases for uh for the force sensing technology. Thank

Passages & reports (3)
  • and how do you think it could evolve over time? And
  • would
  • also just appreciate any color in terms of kind of primary use cases for uh for the force …

Speaker unclear

?you. Hey,

Passages & reports (1)
  • you. Hey,

Speaker 4

Adam,

Passages & reports (1)
  • Adam,

Speaker 2

I appreciate the question. Maybe I'll start with a quick story that just uh happened. And so ?a few weeks ago we hosted this surgeon event here where the early surgeons that were involved with DaVinci uh came to our campus and and we had a nice event. I would I had the opportunity to meet with a very ?uh well versed prostatectomy surgeon who has done over 10,000 cases, and he showed me his results that uh were a comparative between XI and DaVinci Five.

And he was showing uh the return of of uh potency in this case from time zero through twelve months.
And so uh and you watch it gradually increase from ?uh uh about fifty percent or so out of the gate to above about 80%. And he has very good data. He's one of the world's leading surgeons. And then he laid his recent DaVinci 5 experience on top of it, and it moved the entire curve up by about 10 points. ?

And
so, and I asked him why, and he attributed that to force feedback and the ability to sense those forces and be that much gentler around the nerve-sparing portion of the prostatectomy, which led to those results. And so that's maybe a little bit of color about how force feedback can make a difference in outcomes and and even with surgeons who are very, very uh high up in their use of DaVinci.

Passages & reports (11)
  • I appreciate the question. Maybe I'll start with a quick story that just uh happened. And …
  • a
  • few weeks ago we hosted this surgeon event here where the early surgeons that were involve…
  • uh
  • well versed prostatectomy surgeon who has done over 10,000 cases, and he showed me his res…
  • And so uh and you watch it gradually increase from
  • uh
  • uh about fifty percent or so out of the gate to above about 80%. And he has very good data…
  • And
  • so, and I asked him why, and he attributed that to force feedback and the ability to sense…
  • outcomes and and even with surgeons who are very, very uh high up in their use of DaVinci.

Speaker 4

In terms of adoption, this quarter about eight percent of DaVinci Five cases involve uh force feedback. That's kind of been ?kind of a slow increase from where we've started. ?Uh we only got full, full supply later in the quarter, so that affected the eight percent. I I would I would say this our

Passages & reports (5)
  • In terms of adoption, this quarter about eight percent of DaVinci Five cases involve uh fo…
  • kind
  • of a slow increase from where we've started.
  • Uh
  • we only got full, full supply later in the quarter, so that affected the eight percent. I …

Speaker unclear

?our

Passages & reports (1)
  • our

Speaker 3

ambitions are for that number to be that penetration number to be quite a bit higher. Obviously to some extent that requires us to to create the evidence that supports the value propositions. The teams are working hard on

Passages & reports (1)
  • ambitions are for that number to be that penetration number to be quite a bit higher. Obvi…

Speaker 4

that and we have our eye ?very close in in terms ?of how

Passages & reports (5)
  • that and we have our eye
  • very close in in
  • terms
  • of
  • how

Speaker unclear

?that gets

Passages & reports (1)
  • that gets

Speaker 3

adopted and

Passages & reports (1)
  • adopted and

Speaker unclear

?that the actual value of

Passages & reports (1)
  • that the actual value of

Speaker 4

using the force feedback instruments is is well understood. I would just say there are other offsets as we described the sp INA per procedure

Passages & reports (1)
  • using the force feedback instruments is is well understood. I would just say there are oth…

Speaker 3

is quite a bit higher than than multi pool, and

Passages & reports (1)
  • is quite a bit higher than than multi pool, and

Speaker unclear

?and obviously those procedures are

Passages & reports (1)
  • and obviously those procedures are

Speaker 3

growing ?at a much higher rate. And

Passages & reports (3)
  • growing
  • at
  • a much higher rate. And

Speaker unclear

?and

Passages & reports (1)
  • and

Speaker 4

on DaVinci 5, because of the integrated

Passages & reports (1)
  • on DaVinci 5, because of the integrated

Speaker 3

insuflation,

Passages & reports (1)
  • insuflation,

Speaker 4

when integrated insufflation is used, which is about 85% of the time, there's an additional about $100 per procedure

Passages & reports (1)
  • when integrated insufflation is used, which is about 85% of the time, there's an additiona…

Speaker unclear

?for the

Passages & reports (1)
  • for the

Speaker 2

tube sets

Passages & reports (1)
  • tube sets

Speaker unclear

?that connect to the insufflator. So th

Passages & reports (1)
  • that connect to the insufflator. So th

Speaker 3

those three can ?can drive offsets in terms of the three to five percent, and they generally would be expected to grow at a faster pace than the base INA.

Passages & reports (3)
  • those three can
  • can
  • drive offsets in terms of the three to five percent, and they generally would be expected …

Speaker 0

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Our next question comes from the line of Jason Bitford with Raymond James and Associates. Your line is open.

Passages & reports (1)
  • Our next question comes from the line of Jason Bitford with Raymond James and Associates. …

Speaker 7

Uh good

Passages & reports (1)
  • Uh good

Speaker unclear

?afternoon

Passages & reports (1)
  • afternoon

Speaker 3

and thanks for taking the question. Maybe just for ?Jamie. Um on the EUP, how ?long will it take you to fully

Passages & reports (5)
  • and thanks for taking the question. Maybe just for
  • Jamie. Um on the
  • EUP, how
  • long will
  • it take you to fully

Speaker 7

implement the the program? Meaning

Passages & reports (1)
  • implement the the program? Meaning

Speaker unclear

?when do you expect to see the three to five percent

Passages & reports (1)
  • when do you expect to see the three to five percent

Speaker 7

gross uh gross impact on revenue per

Passages & reports (1)
  • gross uh gross impact on revenue per

Speaker 2

procedure and is there any way to kind of frame the expected in impact in in 27? Thanks.

Passages & reports (1)
  • procedure and is there any way to kind of frame the expected in impact in in 27? Thanks.

Speaker 4

Yeah, the w it will be country by country. The first is the US. As I said, that submission is in process, so we'd expect to start to to

Passages & reports (1)
  • Yeah, the w it will be country by country. The first is the US. As I said, that submission…

Speaker 3

roll that

Passages & reports (1)
  • roll that

Speaker 4

out sometime later in Q1, depending on on obviously when we get clearance. Um

Passages & reports (1)
  • out sometime later in Q1, depending on on obviously when we get clearance. Um

Speaker 3

Europe it would be next, and that's not till the second half of uh 27, and then some of the other markets

Passages & reports (1)
  • Europe it would be next, and that's not till the second half of uh 27, and then some of th…

Speaker 4

of just before or just after that. So I don't think we get to the full impact till the end of the year, frankly.

Passages & reports (1)
  • of just before or just after that. So I don't think we get to the full impact till the end…

Speaker 0

Thank ?you. Please stand by for our next question. ?Our next question comes from the line of Matt Taylor with Jeff Reese. The line is

Passages & reports (5)
  • Thank
  • you.
  • Please stand by for our next question.
  • Our
  • next question comes from the line of Matt Taylor with Jeff Reese. The line is

Speaker unclear

?open.

Passages & reports (1)
  • open.

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 1

uh thanks

Passages & reports (1)
  • uh thanks

Speaker 7

for taking the question.

Passages & reports (1)
  • for taking the question.

Speaker unclear

?I I did want

Passages & reports (1)
  • I I did want

Speaker 5

to follow up on

Passages & reports (1)
  • to follow up on

Speaker unclear

?the uh settlement that you talked about today. You mentioned it's you know one time, no fault and just provide some certainty for your customers.

Passages & reports (1)
  • the uh settlement that you talked about today. You mentioned it's you know one time, no fa…

Speaker 3

I guess ?just wondering, you know, uh what what this practically means for your customers and and how they move

Passages & reports (3)
  • I guess
  • just
  • wondering, you know, uh what what this practically means for your customers and and how th…

Speaker unclear

?on

Passages & reports (1)
  • on

Speaker 7

from that. And ?um if you could uh ?just talk about um remanufacturing ?in general and whether that's been any any kind of real headwind.

Passages & reports (7)
  • from that. And
  • um if
  • you could uh
  • just
  • talk about um remanufacturing
  • in general
  • and whether that's been any any kind of real headwind.

Speaker 2

Yeah sure. Um maybe I'll start and you know Gary Lopez weigh ?in. So th this this uh settlement really is an agreement with our customers specifically regarding third party instrument remanufacturers and third party service providers. And I think the important part here is that it provides a clear framework on how we'll continue to work together in those two specific areas. ?And it lets us focus ?on really the things that are important.

So advancing the safety, quality, and security of our products
?for surgeons, care teams, and their patients. And so we believe that this certainty that it provides allows us to move forward and really focus on uh building value with our customers.

Passages & reports (10)
  • Yeah sure. Um maybe I'll start and you know Gary Lopez weigh
  • in.
  • So th this this uh settlement really is an agreement with our customers specifically regar…
  • areas.
  • And
  • it lets us focus
  • on
  • really the things that are important. So advancing the safety, quality, and security of ou…
  • for
  • surgeons, care teams, and their patients. And so we believe that this certainty that it pr…

Speaker 1

Yeah just just

Passages & reports (1)
  • Yeah just just

Speaker unclear

?to add briefly, I think the resolution really

Passages & reports (1)
  • to add briefly, I think the resolution really

Speaker 3

strengthens our customer relationships ?and it just provides a defined framework

Passages & reports (3)
  • strengthens our customer relationships
  • and
  • it just provides a defined framework

Speaker unclear

?for

Passages & reports (1)
  • for

Speaker 2

how we ?work together on instruments and services.

Passages & reports (3)
  • how we
  • work
  • together on instruments and services.

Speaker 0

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Our next question comes from the line of Chris Pasquale with Barclays. Your line is open.

Passages & reports (1)
  • Our next question comes from the line of Chris Pasquale with Barclays. Your line is open.

Speaker 7

Thanks.

Passages & reports (1)
  • Thanks.

Speaker unclear

?I appreciate taking the question.

Passages & reports (1)
  • I appreciate taking the question.

Speaker 3

I want to ask ?about margins. You guys have done a ?great job improving profitability over the past few years. This quarter was better than expected. Streets modeling operating margin flat next year. So while I appreciate you don't really want to get into 27 in detail right now, ?you talked about offsetting the gross margin headwind from extended use. Are there any other uh considerations

Passages & reports (7)
  • I want to ask
  • about
  • margins. You guys have done a
  • great job improving
  • profitability over the past few years. This quarter was better than expected. Streets mode…
  • you
  • talked about offsetting the gross margin headwind from extended use. Are there any other u…

Speaker unclear

?that we should take into account as we think about you know profitability and your ability to continue to expand

Passages & reports (1)
  • that we should take into account as we think about you know profitability and your ability…

Speaker 3

margins here ?going forward? Thank

Passages & reports (3)
  • margins here
  • going
  • forward? Thank

Speaker unclear

?you. Yeah,

Passages & reports (1)
  • you. Yeah,

Speaker 4

I think I think what we've said for ?some time now is kind of the range of where we'd expect to be on operating margin is between 35% and 40%. And I think that's frankly best in class in in MedTech. As we think about it from a strategy perspective, our lean is to to invest, invest in areas where we can innovate and

Passages & reports (4)
  • I think I think what we've said for
  • some time
  • now is kind of the range of where we'd expect to be on operating margin is between 35% and…
  • innovate and

Speaker 3

bring differentiated capability to to our customers and their patients,

Passages & reports (1)
  • bring differentiated capability to to our customers and their patients,

Speaker unclear

?but also to

Passages & reports (1)
  • but also to

Speaker 4

support investments that allow us to

Passages & reports (1)
  • support investments that allow us to

Speaker unclear

?to grow

Passages & reports (1)
  • to grow

Speaker 3

at accelerated rates so that we ?can again serve more patients and where we are right now 41

Passages & reports (3)
  • at accelerated rates so that we
  • can
  • again serve more patients and where we are right now 41

Speaker unclear

?42 percent we we have the capacity

Passages & reports (1)
  • 42 percent we we have the capacity

Speaker 3

to to to invest and so as we finish our planning process then we'll

Passages & reports (1)
  • to to to invest and so as we finish our planning process then we'll

Speaker 4

evaluate that that ?carefully I'm not ready to say what we'll do on operating expenses um but certainly if there are opportunities for uh for us to do what I just described then we'll use that capacity to invest. We'll provide that guidance obviously in in in January.

Passages & reports (3)
  • evaluate that that
  • carefully I'm
  • not ready to say what we'll do on operating expenses um but certainly if there are opportu…

Speaker 2

Okay. That was our last question. Thank you for the questions. In closing, we continue to believe there's a substantial and durable opportunity to fundamentally improve surgery and acute interventions. ?Our teams continue to work closely with hospitals, physicians, and care teams in pursuit of what our customers have termed the quintopol aim. Better and more predictable patient outcomes, better experiences for patients, better experiences for their care teams, lower total cost of care, and finally increased access to care. ?

We
believe value creation in surgery and acute care is foundationally human. It flows from respect for and understanding of patients and care teams and their needs in their environment. ?At intuitive, we envision a future of care that is less invasive and profoundly better, where diseases are identified earlier and treated quickly so patients can get back to what matters most. Thank you for your support on this extraordinary journey.

We look forward to talking with you again in three months.

Passages & reports (7)
  • Okay. That was our last question. Thank you for the questions. In closing, we continue to …
  • Our
  • teams continue to work closely with hospitals, physicians, and care teams in pursuit of wh…
  • We
  • believe value creation in surgery and acute care is foundationally human. It flows from re…
  • At
  • intuitive, we envision a future of care that is less invasive and profoundly better, where…

Speaker 0

Ladies and gentlemen, that concludes today's conference call. Thank you for your participation. You may now disconnect.

Passages & reports (1)
  • Ladies and gentlemen, that concludes today's conference call. Thank you for your participa…
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 0. Unassigned words: 360. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-15T21:34:51.354Z.
Transcript version v1-93c96affe1409cd86050 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.